Skip to main content

Table 1 Patient demographics and baseline disease characteristics

From: First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Parameter/characteristic Lumiracoxib 400 mg once daily (n = 144) Celecoxib 200 mg twice daily (n = 145) Placebo (n = 75)
Age (years; mean ± SD) 64.7 ± 7.8 65.3 ± 9.5 64.8 ± 9.0
Males (n [%]) 66 (45.8) 54 (37.2) 33 (44.0)
Females (n [%]) 78 (54.2) 91 (62.8) 42 (56.0)
Disease duration (years; mean ± SD) 7.3 ± 6.7 7.5 ± 6.7 7.6 ± 8.6
VAS actuala pain intensity (mm; mean ± SD) 65.8 ± 11.5 64.1 ± 11.5 64.4 ± 12.4
VAS worstb pain intensity (mm; mean ± SD) 75.7 ± 11.5 75.5 ± 11.8 74.3 ± 11.2
VAS averagec pain intensity (mm; mean ± SD) 57.9 ± 12.5 56.9 ± 11.6 57.0 ± 14.8
WOMAC™ scores (mean ± SD)    
   Total 52.3 ± 12.6 53.9 ± 12.5 53.2 ± 11.6
   Pain 10.6 ± 2.9 11.1 ± 2.9 10.8 ± 2.6
   Stiffness 4.0 ± 1.7 4.0 ± 1.7 4.1 ± 1.3
   DPDA 37.8 ± 9.2 38.8 ± 9.2 38.3 ± 8.7
  1. aVAS actual pain intensity = mean of 3-hour and 5-hour assessments. bVAS worst pain intensity = worst pain intensity in the past 12 hours. cVAS average pain intensity = average pain intensity in the past 12 hours. DPDA, difficulty in performing daily activities; SD, standard deviation; VAS, visual–analogue scale; WOMAC™, Western Ontario and McMaster Universities Osteoarthritis Index.